2015 SUPPORT TRIAL M Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure (CHF) prospective, open-label, randomized controlled trial Objective: to examine whether an additive treatment with an ARB, olmesartan, reduces the mortality and morbidity of hypertensive patients with stable CHF 1147 Patients Inclusion criteria: Patients aged ≥20 & <80 […]